NASDAQ:OTLK Outlook Therapeutics (OTLK) Stock Price, News & Analysis $6.27 -0.20 (-3.09%) (As of 11/12/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Outlook Therapeutics Stock (NASDAQ:OTLK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Outlook Therapeutics alerts:Sign Up Key Stats Today's Range$6.15▼$6.6150-Day Range$4.94▼$8.0152-Week Range$4.61▼$12.85Volume266,692 shsAverage Volume347,328 shsMarket Capitalization$148.35 millionP/E RatioN/ADividend YieldN/APrice Target$48.20Consensus RatingBuy Company OverviewOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Read More… Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Outlook Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks37th Percentile Overall ScoreOTLK MarketRank™: Outlook Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 781st out of 986 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOutlook Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOutlook Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Outlook Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Outlook Therapeutics are expected to grow in the coming year, from ($3.84) to ($2.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Outlook Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Outlook Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Outlook Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.21% of the float of Outlook Therapeutics has been sold short.Short Interest Ratio / Days to CoverOutlook Therapeutics has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in Outlook Therapeutics has recently increased by 8.03%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOutlook Therapeutics does not currently pay a dividend.Dividend GrowthOutlook Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted21.21% of the float of Outlook Therapeutics has been sold short.Short Interest Ratio / Days to CoverOutlook Therapeutics has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in Outlook Therapeutics has recently increased by 8.03%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News Sentiment0.94 News SentimentOutlook Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Outlook Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 19 people have searched for OTLK on MarketBeat in the last 30 days. This is a decrease of -34% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Outlook Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Outlook Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $28,450.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Outlook Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 11.20% of the stock of Outlook Therapeutics is held by institutions.Read more about Outlook Therapeutics' insider trading history. Receive OTLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address OTLK Stock News HeadlinesOutlook Therapeutics® to Present at the Guggenheim Healthcare Innovation ConferenceNovember 6, 2024 | globenewswire.comCautious Outlook on United Therapeutics Amid Revenue Growth and Competitive PressuresNovember 1, 2024 | markets.businessinsider.comTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future. November 12, 2024 | Crypto 101 Media (Ad)ULM College of Business and Social Sciences to host Outlook Summit at Bayou Pointe Event Center on November 8October 29, 2024 | msn.comPositive Outlook on Viking Therapeutics Driven by Promising VK2735 Obesity ProgramOctober 25, 2024 | markets.businessinsider.comOutlook Therapeutics: Poised to Capitalize on Market Opportunities with LYTENAVA Amidst Industry ShiftsOctober 19, 2024 | markets.businessinsider.comOutlook Therapeutics® Participates in a Virtual Investor CEO Connect SegmentOctober 17, 2024 | finance.yahoo.comEconomic Outlook Conference will “Re-Imagine” the future of the Ohio ValleyOctober 12, 2024 | msn.comSee More Headlines OTLK Stock Analysis - Frequently Asked Questions How have OTLK shares performed this year? Outlook Therapeutics' stock was trading at $7.88 at the beginning of 2024. Since then, OTLK stock has decreased by 20.4% and is now trading at $6.27. View the best growth stocks for 2024 here. How were Outlook Therapeutics' earnings last quarter? Outlook Therapeutics, Inc. (NASDAQ:OTLK) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.23. When did Outlook Therapeutics' stock split? Outlook Therapeutics's stock reverse split on the morning of Thursday, March 14th 2024. The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Outlook Therapeutics' major shareholders? Top institutional shareholders of Outlook Therapeutics include Charles Schwab Investment Management Inc. (0.22%) and Christensen King & Associates Investment Services Inc. (0.04%). Insiders that own company stock include Jeff Evanson, Terry Dagnon, Kurt J Hilzinger, Lawrence A Kenyon, Yezan Munther Haddadin, C Russell Trenary III and Ghiath M Sukhtian. View institutional ownership trends. How do I buy shares of Outlook Therapeutics? Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Outlook Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Outlook Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Intel (INTC) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings8/14/2024Today11/12/2024Next Earnings (Estimated)12/27/2024Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OTLK CUSIPN/A CIK1649989 Webwww.outlooktherapeutics.com Phone(609) 619-3990FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$48.20 High Stock Price Target$100.00 Low Stock Price Target$30.00 Potential Upside/Downside+668.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($10.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,980,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-160.88% Debt Debt-to-Equity RatioN/A Current Ratio1.07 Quick Ratio1.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.11) per share Price / Book-5.65Miscellaneous Outstanding Shares23,660,000Free Float22,852,000Market Cap$148.35 million OptionableOptionable Beta0.62 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NASDAQ:OTLK) was last updated on 11/12/2024 by MarketBeat.com Staff From Our PartnersTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredFREE investing Class TOMORROW + 2 FREE BonusesOver the last 37 years on Wall Street, I've developed a unique investing strategy that allows me to find stock...Unstoppable Prosperity | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored6-Figure Target for BTC by 2025According to Steven Lubka, head of a private equity firm with over $250M in assets under management, "Bitcoin ...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCritical warning from the mountains of CarolinaNvidia CEO Jensen Huang says Big Tech will spend over $1 trillion on data centers. And that still might not...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.